Clinical trials: Rejection
Kidney Transplantation
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin…
- Trial name
- NCT00235781
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Immunity, Cellular
Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients
The study will prospectively determine the clinical utility of non-pathogen specific cellular immunity assessment using the Quantiferon-Monitor to quantify the degree of immunosuppression.
- Trial name
- QTF-Monitor (NCT02560857)
- Testing
- Quantiferon-Monitor assay
- Where
- Canada
- Volunteers
- 151 people
- Sponsor
- Deepali Kumar
Lung Transplant Rejection
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.
- Trial name
- NCT06309628
- Testing
- Breathe sample
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Paragonix Technologies
Renal Transplant Rejection, Immune Repertoire
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue…
- Conditions
- Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity
- Trial name
- ALL-T-COPIES (NCT03422224)
- Testing
- Mixed lymphocyte reaction
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Liver Transplant
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
To determine whether long-term maintenance therapy with a single drug (Myfortic) applied using advanced immunologic monitoring tools in selected patients can lead to superior native kidney function at 2 years without resulting in…
- Trial name
- NCT01230502
- Testing
- Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy, data and sample collection
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Graft Rejection
Molecular HistoMx Assessment for Kidney Transplant Rejection and Management
Transcriptomic analysis of kidney biopsies has demonstrated the potential to improve diagnosis of graft rejection. Molecular assessment of kidney graft rejection based on the Banff Human Organ Transplant consensus gene panel is…
- Trial name
- NCT07347353
- Testing
- No intervention
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Liver Transplant Rejection
Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration
This is a randomized controlled trial in which the safety and feasibility of cell therapy medicinal product shall be measured by comparing the variables of the response after treatment compared to baseline prior to…
- Trial name
- NCT01745731
- Testing
- Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Graft Failure
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an…
- Trial name
- NCT00472329
- Testing
- Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Kidney Transplant Rejection, Kidney Transplant; Complications
Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients
The renal biopsy (RB) represents the gold-standard for the diagnosis of acute renal transplant rejection (AR), and allows early verification of a so-called "subclinical" rejection, ie without any clinical or biological…
- Trial name
- NCT04702022
- Testing
- 18FDG PET / CT
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University of Liege
Graft Rejection, Hepatocellular Carcinoma
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC. The combination of the ICI and other treatment regimens (Anti-VEGF, locoregional therapies et al) produced superior results in patients with…
- Conditions
- Graft Rejection, Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT05913583
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Immunosuppression Management, Biomarkers / Blood
PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)
This is an observational, prospective, multi-center trial designed to evaluate clinical outcomes in kidney transplant recipients undergoing TruGraf and TRAC monitoring. Approximately 15 U.S. sites
- Conditions
- Immunosuppression Management, Biomarkers / Blood, Subclinical Rejection, Biopsy
- Trial name
- PIONEER (NCT07231328)
- Testing
- There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection.
- Volunteers
- 600 people
- Sponsor
- Transplant Genomics, Inc.
Antibody-mediated Rejection, Autoimmune Reaction Mediated by Immune Complex
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases.
- Trial name
- NCT02533596
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Hannover Medical School
Rejection; Transplant, Liver, Liver Failure
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal.
- Conditions
- Rejection; Transplant, Liver, Liver Failure, Liver Diseases
- Trial name
- LIBERATE (NCT05234190)
- Testing
- QEL-001
- Where
- 10 sites in Belgium, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Quell Therapeutics Limited
Allosensitization, Kidney Transplant Rejection
Desensitization in Kidney Allograft Using Daratumumab
Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality.
- Conditions
- Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
- Trial name
- DARDAR (NCT04204980)
- Testing
- Daratumumab dose escalation, Daratumumab full dose
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiac Transplant Rejection, Qt Interval, Variation in
Home Electrocardiogram (ECG) Monitoring After Heart Transplantation
The long-term goal of this research is to apply novel technology for detection of donor organ (allograft) rejection to improve patient outcomes following heart transplantation.
- Trial name
- NEW HEART (NCT01365806)
- Where
- 3 sites in United States
- Volunteers
- 345 people
- Sponsor
- University of California, Los Angeles
Alcohol-Induced Disorders, Ostracism
Role of Adverse Childhood Events and Rejection Sensitivity on Alcohol Use in Recently Withdrawn Individuals With Alcohol Use Disorder
Low utilization of addiction treatment is a public health problem. A number of factors are associated with lack of treatment, including public stigma, self-stigma, and beliefs that people with addiction should solve their problem…
- Trial name
- TRAC (NCT05787106)
- Testing
- Cyberball task
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lung Transplant Rejection, Primary Graft Dysfunction
Exhaled Breath Particles in Lung Transplantation
Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years.
- Conditions
- Lung Transplant Rejection, Primary Graft Dysfunction, Chronic Rejection of Lung Transplant
- Trial name
- NCT05375149
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Kidney Transplant Failure and Rejection, Pediatric Kidney Disease
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Registry study in which data of all pediatric kidney recipients in the Netherlands (registered in the Nederlandse Orgaan Transplantatie Registry) are studied to develop a risk calculator for graft loss.
- Trial name
- NCT05388955
- Testing
- None, transplantation recipients
- Volunteers
- 1,425 people
- Sponsor
- Radboud University Medical Center
Heart Transplantation
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function.
- Trial name
- NCT02554955
- Testing
- Daclizumab, Mycophenolate mofetil, Silrolimus
- Where
- 14 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche